231 related articles for article (PubMed ID: 30239896)
21. Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages.
Liang XH; Sun H; Shen W; Crooke ST
Nucleic Acids Res; 2015 Mar; 43(5):2927-45. PubMed ID: 25712094
[TBL] [Abstract][Full Text] [Related]
22. Chloroquine and cytosolic galectins affect endosomal escape of antisense oligonucleotides after Stabilin-mediated endocytosis.
Pandey E; Harris EN
Mol Ther Nucleic Acids; 2023 Sep; 33():430-443. PubMed ID: 37575283
[TBL] [Abstract][Full Text] [Related]
23. ER-to-Golgi transport by COPII vesicles in Arabidopsis involves a ribosome-excluding scaffold that is transferred with the vesicles to the Golgi matrix.
Kang BH; Staehelin LA
Protoplasma; 2008 Dec; 234(1-4):51-64. PubMed ID: 18810574
[TBL] [Abstract][Full Text] [Related]
24. Insights into innate immune activation via PS-ASO-protein-TLR9 interactions.
Pollak AJ; Zhao L; Vickers TA; Huggins IJ; Liang XH; Crooke ST
Nucleic Acids Res; 2022 Aug; 50(14):8107-8126. PubMed ID: 35848907
[TBL] [Abstract][Full Text] [Related]
25. Differential Uptake of Antisense Oligonucleotides in Mouse Hepatocytes and Macrophages Revealed by Simultaneous Two-Photon Excited Fluorescence and Coherent Raman Imaging.
Mukherjee P; Aksamitiene E; Alex A; Shi J; Bera K; Zhang C; Spillman DR; Marjanovic M; Fazio M; Seth PP; Frazier K; Hood SR; Boppart SA
Nucleic Acid Ther; 2022 Jun; 32(3):163-176. PubMed ID: 34797690
[TBL] [Abstract][Full Text] [Related]
26. Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines.
Linnane E; Davey P; Zhang P; Puri S; Edbrooke M; Chiarparin E; Revenko AS; Macleod AR; Norman JC; Ross SJ
Nucleic Acids Res; 2019 May; 47(9):4375-4392. PubMed ID: 30927008
[TBL] [Abstract][Full Text] [Related]
27. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
Shen W; De Hoyos CL; Migawa MT; Vickers TA; Sun H; Low A; Bell TA; Rahdar M; Mukhopadhyay S; Hart CE; Bell M; Riney S; Murray SF; Greenlee S; Crooke RM; Liang XH; Seth PP; Crooke ST
Nat Biotechnol; 2019 Jun; 37(6):640-650. PubMed ID: 31036929
[TBL] [Abstract][Full Text] [Related]
28. Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver.
Donner AJ; Wancewicz EV; Murray HM; Greenlee S; Post N; Bell M; Lima WF; Swayze EE; Seth PP
Nucleic Acid Ther; 2017 Aug; 27(4):209-220. PubMed ID: 28448194
[TBL] [Abstract][Full Text] [Related]
29. Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes.
Tanowitz M; Hettrick L; Revenko A; Kinberger GA; Prakash TP; Seth PP
Nucleic Acids Res; 2017 Dec; 45(21):12388-12400. PubMed ID: 29069408
[TBL] [Abstract][Full Text] [Related]
30. Phosphorothioate oligonucleotides can displace NEAT1 RNA and form nuclear paraspeckle-like structures.
Shen W; Liang XH; Crooke ST
Nucleic Acids Res; 2014 Jul; 42(13):8648-62. PubMed ID: 25013176
[TBL] [Abstract][Full Text] [Related]
31. Systematic Analysis of Chemical Modifications of Phosphorothioate Antisense Oligonucleotides that Modulate Their Innate Immune Response.
Pollak AJ; Zhao L; Crooke ST
Nucleic Acid Ther; 2023 Apr; 33(2):95-107. PubMed ID: 36749166
[TBL] [Abstract][Full Text] [Related]
32. Solid-Phase Separation of Toxic Phosphorothioate Antisense Oligonucleotide-Protein Nucleolar Aggregates Is Cytoprotective.
Liang XH; De Hoyos CL; Shen W; Zhang L; Fazio M; Crooke ST
Nucleic Acid Ther; 2021 Apr; 31(2):126-144. PubMed ID: 33534636
[TBL] [Abstract][Full Text] [Related]
33. Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides.
Bailey JK; Shen W; Liang XH; Crooke ST
Nucleic Acids Res; 2017 Oct; 45(18):10649-10671. PubMed ID: 28977508
[TBL] [Abstract][Full Text] [Related]
34. A novel and translational role for autophagy in antisense oligonucleotide trafficking and activity.
Ochaba J; Powers AF; Tremble KA; Greenlee S; Post NM; Matson JE; MacLeod AR; Guo S; Aghajan M
Nucleic Acids Res; 2019 Dec; 47(21):11284-11303. PubMed ID: 31612951
[TBL] [Abstract][Full Text] [Related]
35. Integrated Assessment of the Clinical Performance of GalNAc
Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
[TBL] [Abstract][Full Text] [Related]
36. Phosphorothioate modified oligonucleotide-protein interactions.
Crooke ST; Vickers TA; Liang XH
Nucleic Acids Res; 2020 Jun; 48(10):5235-5253. PubMed ID: 32356888
[TBL] [Abstract][Full Text] [Related]
37. Distinct stages in the recognition, sorting, and packaging of proTGFα into COPII-coated transport vesicles.
Zhang P; Schekman R
Mol Biol Cell; 2016 Jun; 27(12):1938-47. PubMed ID: 27122606
[TBL] [Abstract][Full Text] [Related]
38. Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides.
Østergaard ME; De Hoyos CL; Wan WB; Shen W; Low A; Berdeja A; Vasquez G; Murray S; Migawa MT; Liang XH; Swayze EE; Crooke ST; Seth PP
Nucleic Acids Res; 2020 Feb; 48(4):1691-1700. PubMed ID: 31980820
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Phosphorus and Non-Phosphorus Neutral Oligonucleotide Backbones for Enhancing Therapeutic Index of Gapmer Antisense Oligonucleotides.
Vasquez G; Migawa MT; Wan WB; Low A; Tanowitz M; Swayze EE; Seth PP
Nucleic Acid Ther; 2022 Feb; 32(1):40-50. PubMed ID: 34698585
[TBL] [Abstract][Full Text] [Related]
40. RNA modifications can affect RNase H1-mediated PS-ASO activity.
Doxtader Lacy KA; Liang XH; Zhang L; Crooke ST
Mol Ther Nucleic Acids; 2022 Jun; 28():814-828. PubMed ID: 35664704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
